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Abstract
Recently, the ubiquitin proteasome system (UPS) has matured as a drug discovery arena, largely on
the strength of the proven clinical activity of the proteasome inhibitor Velcade in multiple myeloma.
Ubiquitin ligases tag cellular proteins, such as oncogenes and tumor suppressors, with ubiquitin.
Once tagged, these proteins are degraded by the proteasome. The specificity of this degradation
system for particular substrates lies with the E3 component of the ubiquitin ligase system (ubiquitin
is transferred from an E1 enzyme to an E2 enzyme and finally, thanks to an E3 enzyme, directly to
a specific substrate). The clinical effectiveness of Velcade (as it theoretically should inhibit the
output of all ubiquitin ligases active in the cell simultaneously) suggests that modulating specific
ubiquitin ligases could result in an even better therapeutic ratio. At present, the only ubiquitin ligase
leads that have been reported inhibit the degradation of p53 by Mdm2, but these have not yet been
developed into clinical therapeutics. In this review, we discuss the biological rationale, assays,
genomics, proteomics and three-dimensional structures pertaining to key targets within the UPS
(SCFSkp2 and APC/C) in order to assess their drug development potential.
Publication history: Republished from Current BioData's Targeted Proteins database (TPdb;
http://www.targetedproteinsdb.com).
Function
The known roles of two RING E3 ubiquitin ligase com-
plexes, the SCF ligases and the anaphase-promoting com-
plex or cyclosome (APC/C), exemplify the cellular utility
of regulated protein degradation. Both these complexes
execute a precisely timed degradation of key proteins in
the cell cycle [1-3]. Degradation ensures that the conse-
quences are unidirectional and temporarily irreversible,
intrinsic requirements of passage through a cell division
cycle checkpoint [4]. SCF complexes rely on their F-box
protein component as a substrate-specific adaptor, and it
is therefore the F-box protein (and the cellular activity of
its targeted substrate) that determines the genetic and cel-
lular effect of any particular SCF complex [5]. A summary
of F-box proteins and their known substrates and func-
tions has recently been published [6]. The function of the
APC/C is more closely tied to the cell cycle machinery: this
E3 ligase mediates progression through and exit from
mitosis, and the maintenance of the G0/G1 state [7].
SCFSkp2 ubiquitylates the Cdk inhibitor p27 in the pres-
ence of the small accessory factor Cks1 [8]. The ubiquit-
ylation is dependent on a specific Cdk phosphorylation
site on p27, and was demonstrated in vitro using purified
components, as well as in cell cycle arrested cellular
extracts and in mammalian cells using RNAi. This phos-
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phorylation site and Cks1 form a complex, the binding of
which to Skp2 has now been crystallographically visual-
ized [9]. The three-dimensional structure of the complex
perfectly recapitulates the biochemistry of the tripartite
interaction.
The APC/C has a similarly convincing mechanism, at least
for part of its function. The APC/C comes in two forms
depending on whether it incorporates the subunit Cdh1
or the subunit Cdc20, both from the Fizzy family of pro-
teins [10]. The two different forms play distinct, high
impact roles in the cell cycle. Timely degradation of
securins and mitotic cyclins via the APC/CCdc20 (demon-
strated in fission yeast studies) accomplishes the met-
aphase to anaphase transition and the exit from mitosis,
respectively, thus providing a dramatic illustration of how
the cell can biochemically accomplish a precise, rapid
ultrastructural event like chromatid separation [11].
Clearly, transcription and translation are not sufficiently
rapid or compartment-specific to accomplish such a large
cellular movement at precisely the right time. Instead, the
immense, activated machinery needed for the movement
of sister chromatids is assembled with a key brake, the
securins, in place [12]. When assembly is complete and
the appropriate signals converge, the brake is degraded
and the machinery seeks its equilibrium, which results in
separated chromatids [11]. Concomitant degradation of
the mitotic cyclins via the APC/CCdc20 resets the driving
force of the cell cycle (Cdk activity) to zero for the G1
phase of the next cell cycle [12].
As demonstrated in elegant yeast studies, APC/CCdh1 con-
tributes to the degradation of mitotic cyclin at the end of
mitosis, and stays active during the next G1, thereby
inducing the degradation of a variety of pro-S phase and
pro-mitotic substrates [10]. APC/CCdh1 is now known to
mediate the degradation of both Cdc20 and, surprisingly,
its G1 counterpart Skp2/Cks1 [1,13].
Only four other SCF ligases, SCFßTrCP, SCFFbw7, SCFFbxl3
and SCFFbx4, have been definitely matched to their sub-
strates in purified biochemistry and cellular studies [5].
For two of these targets, atomic resolution three-dimen-
sional structural data and established in vitro and in vivo
assays are available [14,15]. However, the biological
rationale for both targets is not as consistent across the
spectrum of genetics, biochemistry, cell biology, histopa-
thology and animal studies as it is for Skp2 [16]. Interest-
ingly, although these SCF ligases operate on key substrates
within the cell division cycle (such as PDCD4 [17],
Cdc25A [18,19], Claspin [20], Wee1 [21], Emi1 [22], cyc-
lin E [23] and cyclin D1 [24]), they also influence sub-
strates that are active in prominent cellular signaling
pathways upstream of the cell division cycle, such as the
NFκB pathway, the Notch pathway, the translational
machinery and pathways converging on c-MYC [25] and
c-Jun [16]. Fbw7 may also play a significant role in angio-
genesis, adding to its interest as a target [4]. Given the
multitude of cellular pathways involved, the effects of
inhibitors of SCFßTrCP, SCFFbw7, SCFFbxl3  and SCFFbx4
appear difficult to predict at present.
Disease, mutation, expression
Several lines of evidence directly support a role for Skp2 as
an oncogene in cancer tissues. A multitude of human can-
cer mutations map to the cell cycle arena in which Skp2
operates [4] and, more importantly, several specific find-
ings demonstrate that the biochemical and cellular
growth-promoting effects of Skp2 translate to tumorigen-
esis [26,27]. Histopathologically, Skp2 overexpression
correlates with a higher tumor grade and inversely corre-
lates with prognosis in both epithelial cancer and lym-
phomas [28,29]. In human tumors, low levels of p27
often correlate with Skp2 overexpression, suggesting that
the latter contributes to suppression of p27 abundance in
cancer cells [30,31]. Interestingly, Cks1 is also highly
expressed in certain epithelial cancers [32-36]. The intro-
duction of Skp2 appears to lead to extracellular matrix-
and cell contact-independent growth [37,38] and, signifi-
cantly, Skp2 contributes to the formation of tumors in
animal models [28,39].
Skp2-/- mice, developed by the Nakayama group at AIST
in Japan, are hypoplastic, while p27-/- mice are hyperplas-
tic. Interestingly, a genetically induced double-deficiency
of Skp2 and p27 in this mouse line reversed the Skp2
hypoplastic phenotype and corrected ploidy and mitotic
defects observed in some Skp2-/- mouse tissues [40].
In addition to Skp2, there are at least 67 other F-box pro-
teins available in the human genome to form SCF ligases
[6], a few of which have intriguing phenotypes related to
disease. The most prominent of these is Atrogin, which
cellular extract studies demonstrated can target the muscle
differentiation factor MyoD for degradation [41]. Atrogin
(also known as MAFbx) is upregulated in muscle atrophy
and could play a role in the skeletal wasting seen in neu-
rological disorders such as amyotrophic lateral sclerosis
and cardiac muscle abnormalities in certain cardiomyopa-
thies [42-44]. An F-box protein, Dactylin/Fbw4, is the
cause of a specific genetic skeletal malformation [45] and
another, Fbw8, which associates with Cullin7, is impli-
cated in the developmental genetic abnormality known as
3-M syndrome [46].
Only a few mutations in the APC/C have been described
in human cancers [47], but as expected from the biochem-
ical understanding of Cdh1, they are inactivating muta-
tions. Interestingly, an inhibitor of the APC/C, Emi1, is
also found at high levels in certain epithelial cancers [48].BMC Biochemistry 2007, 8(Suppl 1):S9 http://www.biomedcentral.com/1471-2091/8/S1/S9
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Disease targets and ligands
Of the ubiquitin ligases executing the cell cycle phases and
checkpoints, SCFSkp2 has arguably the strongest biological
rationale as a drug discovery target. Along with estab-
lished ubiquitylation and binding assays, the crystal struc-
ture of SCFSkp2 and previous crystal structures of Skp1-
Skp2 and Cks1 [49-52] are exceptional assets for drug dis-
covery targeting the ubiquitylation of p27 by Skp2. The
established biochemical assays offer the possibility of
high-throughput screening (HTS), and inhibitory com-
pounds may theoretically be designed directly in silico
based on the structure. Though the caveats of protein
interface drug discovery, a historically unproductive
approach, are applicable, two features of the interface
between p27 and Skp2-Cks1 essentially confirm that drug
discovery targeting this interface can succeed [5,53].
Firstly, a single point mutation in Glu185 of p27 abol-
ishes the interaction [9]. This means that a molecule as
small as the amino acid side chain of Glu is likely capable
of disrupting this interface by competition. Secondly, the
pocket in which Glu185 of p27 sits at the interface is suf-
ficiently large to support a drug (Figure 1). Previous sur-
veys have demonstrated that there could be a threshold
pocket size required for an adequate pharmacophore
space, and this one is above the threshold [53,54].
More importantly, the configuration of the SCF and APC/
C as multi-subunit complexes without clear active sites
means that compounds discovered through non-rational
means (e.g. HTS) should have unknown binding sites on
these proteins and unknown sites of interaction in gen-
eral. Indeed, non-F-box binding sites (located, for exam-
ple, at Cullin or Roc1/Rbx1 interfaces) could be
promising therapeutic targets, but only if they are distin-
guishable from F-box binding sites. This is a significant
obstacle to lead optimization and to target specificity.
Nevertheless, compounds promising to inhibit APC/C
and to inhibit the interaction of Skp2 with Cks1 have
been identified [55,56]. Reported by the Vassilev group
(Hoffman-La Roche, Nutley, NJ, USA) that identified the
p53-Mdm2 inhibitor, chemical details of these com-
pounds have not been revealed, although their IC50 is
reported as < 20 uM. The availability of the three-dimen-
sional structure of the key interface allows the possibility
of identifying (in silico or by subsequent crystallographic
experiments) the binding mode of a promising inhibitory
compound. The binding mode, or receptor pharmacoph-
ore space, is then an invaluable asset to lead optimization
and clinical deployment.
Therefore, in the case of SCFSkp2, the resources appear to
be in place for discovery of small molecules inhibiting the
p27-Skp2 interface, and thus the biochemically pure ubiq-
uitylation of p27. Is this ubiquitylation relevant in the
complex environment of the mammalian cell? It appears
yes, since p27 is clearly degraded during the C phase (a
recently proposed term referring to the cell cycle window
of Cdk activity and amplification encompassing S, G2 and
M phases) [8]; since this degradation is crucial for the pro-
gression through the cell cycle and since the growth inhib-
iting effects of stabilizing p27 are easily observed [26,57].
SCFSkp2 also appears to degrade in a similarly precise man-
ner the additional tumor suppressor substrates p21, p57,
p130, FoxO1, Tob1 and perhaps BRCA2. The mitogenic
effects of degradation of each of these additional sub-
strates are reinforcing: multiple parallel investigations on
different substrates converge to the same mitogenic effect
of Skp2 activity.
The biological rationale for targeting Skp2 in human can-
cer is therefore exceptionally strong and consistent, from
atomic structure to pure biochemistry to human cancer
tissues and whole animal mouse homeostasis. The data
suggests, in addition, that Skp2 could be an important tar-
get for inhibition in carcinomas (human epithelial can-
cers), which have seen notoriously few broadly effective
new cancer drugs when compared with hematologic can-
cers. The presence of widely used in vitro and in vivo inter-
action and activity assays further suggests that the tools to
execute a drug discovery program are in place. The
requirement for protein interface targeting appears to be
the only remaining obstacle, perhaps requiring a rational
or structure-based discovery approach. However, the
recent discovery of p53-Mdm2 inhibitors [58-60], as well
as the deep library of crystallographic structural informa-
tion informing the key SCF protein interfaces, suggests
that this obstacle is not insurmountable. Finally, the exist-
ing mouse models set the stage for tissue-specific models
of Skp2 and p27: an important asset in the validation of
Skp2 as a drug target in specific cancers such as skin,
breast, lung or colon.
Although the current understanding positions the APC/C
at the central aspects of both mitosis and the establish-
ment/maintenance of ploidy in the cell, the biological
rationale of modulating the APC/C for cancer is not as
well established as for Skp2 at the tissue and organism lev-
els. Pharmacologic inhibition of APC/CCdc20 might be
expected to inhibit cell growth and, possibly, cause
mitotic catastrophe. This form of the APC/C could there-
fore be an attractive drug target in human cancers. Inhibi-
tion of APC/CCdh1 could blur the boundaries of the cell
cycle phases, possibly leading to genomic instability.
These phenotypes would not be desirable in the context of
human cancer. Agonists of APC/CCdh1 are theoretically
possible, however, since it is a large multi-protein com-
plex. If available, such agonists could be useful anti-cancer
therapeutics, as they would be expected to arrest the cell
cycle in the G0/G1 phase.BMC Biochemistry 2007, 8(Suppl 1):S9 http://www.biomedcentral.com/1471-2091/8/S1/S9
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The interplay between APC/C and SCFSkp2 across the cell
division cycle represents a fascinating aspect of this drug
discovery scenario. One would expect precise feedback
between the two bookend phases of the cell cycle: the
DNA synthesis (S) phase and mitosis (M). The cell would
certainly not benefit from DNA synthesis occurring simul-
taneously with mitosis and vice versa. Indeed, the degra-
dation of Skp2 by APC/CCdh1, the degradation of Emi1 by
SCFßTrCP, and the degradation of Cdc20 by Cdh1 represent
some of the mechanisms by which this synchronization
takes place (for review see [5]). The interdependence of
these factors across the cell cycle phases suggests that spe-
cific small molecule inhibitors could be useful for both
chemical genetic dissection of the details of the system
and for clinical combination therapy (for example an
antagonist of Skp2 and agonist of APC/CCdh1 reinforcing
each other).
Next frontiers
Unfortunately, the technical drug discovery resources tar-
geting the APC/C are limited, mostly due to the immense
size and complexity of this complex, which has at least 12
subunits. Although the APC/C has been purified and fas-
cinating new structural information obtained in the form
of cryo-electron microscopic envelopes [61,62], these are
immature drug discovery resources compared with puri-
fied in vitro assays and atomic resolution crystallographic
structures. Lysate- or cellular-based screening assays could
be employed to find lead compounds influencing the
APC/C, but there is a need for three-dimensional resolu-
tion of key protein interfaces. The APC/C is therefore an
intriguing complex that would benefit from a prior drug
discovery yield from Skp2, but significant gaps remain
both in the validation of this target and in the tools
needed to ensure drug discovery success.
A drug binding pocket of sufficient size coincides with p27 Glu185 in the complex of p27, Cks1 and Skp2 Figure 1
A drug binding pocket of sufficient size coincides with p27 Glu185 in the complex of p27, Cks1 and Skp2. Blue 
ribbon: Skp2. Gold ribbon: Cks1. Green ribbon: p27 peptide. Stick display: pThr187 and Glu185 of p27. Grey/pink geometric 
object: potential drug binding solvent pocket at Cks1-Skp2 interface seen in the absence of p27, as computed by the method of 
An et al. [54]. Inset upper left: zoomed in view of the pocket, pThr187 and Glu185 of p27.BMC Biochemistry 2007, 8(Suppl 1):S9 http://www.biomedcentral.com/1471-2091/8/S1/S9
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The current state-of-the-art clearly maps the SCF ligases
and the APC/C to an emerging network of inter-relation-
ships that drive and time the cell cycle. Small molecule
inhibitors could be wrenches in the works of this key, but
complex, cellular activity that underpins the growth of
cancer cells. SCFSkp2 represents the most mature target in
this context, but fortunately several of the key issues that
will be resolved in targeting Skp2 for drug discovery will
likely apply to the subsequent targeting of the APC/C and
other SCF ubiquitin ligases. These issues include 1)
whether the compounds found to inhibit Skp2 protein
interfaces will have appropriate bioavailability and toxic-
ity profiles; 2) how specific molecules designed for sub-
strate binding interfaces will be for specific substrates (as
opposed to inhibiting all the substrates for a particular
ubiquitin ligase equally) and 3) the final in vivo or clinical
effects of the compounds inhibiting these complexes, the
activity of which will depend on the interplay of the vari-
ous substrates affected.
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